NEW YORK — Menarini Silicon Biosystems said today that it has partnered with Dutch bioinformatics firm BlueBee to develop a cloud-based platform for processing next-generation sequencing data derived from liquid biopsy and formalin-fixed paraffin embedded (FFPE) tissue analysis.
Specific terms of the deal were not disclosed.
Called MSBiosuite, the platform automates the processing of raw sequencing data generated with Menarini's Ampli1 kit for single circulating tumor cells and its DEPArray kit for FFPE tissue analysis. It also provides information on copy number profiling and somatic variants.
"With MSBiosuite, we now offer an integrated data solution that completes our single-cell liquid biopsy and FFPE workflows and will support our customers in getting to actionable results with efficiency and confidence," Menarini Silicon Biosystems CEO Fabio Piazzalunga said in a statement.
Menarini Silicon Biosystems, a subsidiary of Florence, Italy-based Menarini Group, said that MSBiosuite is now available in Europe and is expected to launch in the US later this year.